US FDA pushes for track and trace data standards in latest guidance

By Flora Southey contact

- Last updated on GMT

GettyImages/marekuliasz
GettyImages/marekuliasz
The US FDA has released recommended data standards for drug supply chain trading partners, in a move to standardise track and trace.

The US Food and Drug Administration (FDA) issued the draft guidance this week, which elaborates on industry standards relating to the Drug Supply Chain Security Act (DSCSA).

The DSCSA​ outlines steps to build an electronic, ‘interoperable’ system – meaning to exchange product tracing information accurately, efficiently and consistently – to identify and trace certain prescriptions medicines in the US.

The FDA said the system, which is currently electronic and paper-based, will be electronic only and fully implemented by 2023.

The Standardisation of Data and Documentation Practices for Product Tracing​ draft guidance sets new recommended data standards, to help inform trading partners​ in the drug supply chain – from manufacturers to pharmacies – on the product tracing information they must provide, capture and maintain.

The guidance also offers recommended documentation practices for trading partners in order to meet product tracing requirements – including in situations where they are legally allowed to omit information, said the agency.

Commissioner Scott Gottlieb said the guidance responds to a need to evolve US practices to use the most up-to-date technologies, to impede “increasingly more sophisticated threats” ​to the drug supply system.

“The new steps will reduce the risk of harmful drugs reaching patients by allowing us to identify and trace certain prescription drugs as they are distributed throughout the US,” ​he added.

The FDA also released a guidance outlining its interpretation of terms relating to drug supply chain security.

The Definitions of Suspect Product and Illegitimate Product for Verification Obligations​ draft guidance clarifies the FDA’s interpretation of ‘suspect product’, ‘illegitimate product’, ‘counterfeit’, ‘diverted’, ‘fraudulent transaction’, and ‘unfit for distribution’.

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars